Madrigal Pharmaceuticals, Inc. (MDGL)
427.18
+1.97
(+0.46%)
USD |
NASDAQ |
Nov 13, 16:00
427.18
0.00 (0.00%)
After-Hours: 19:59
Madrigal Pharmaceuticals Gross Profit Margin (Quarterly) : 91.14% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 91.14% |
| June 30, 2026 | 88.91% |
| March 31, 2026 | 91.25% |
| December 31, 2025 | 92.26% |
| September 30, 2025 | 93.57% |
| June 30, 2025 | 95.56% |
| March 31, 2025 | 96.44% |
| December 31, 2024 | 96.31% |
| September 30, 2024 | 96.06% |
| June 30, 2024 | 93.83% |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 |
| Date | Value |
|---|---|
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Insmed, Inc. | 84.12% |
| Alnylam Pharmaceuticals, Inc. | 75.19% |
| Arrowhead Pharmaceuticals, Inc. | 91.15% |
| Cytokinetics, Inc. | 87.67% |
| United Therapeutics Corp. | 88.10% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -26.60% |
| Return on Assets | -11.91% |
| Return on Invested Capital | -16.66% |
| Profit Margin (Quarterly) | 12.86% |
| Operating Margin (Quarterly) | 12.98% |
| Return on Net Operating Assets | -53.89% |